Evan Picard
Evan’s leadership journey has seen him play pivotal roles in shaping business strategies across multiple industries. Before joining MMS, Evan was Vice President of Finance at Parexel, having previously made significant contributions to renowned entities such as Syneos Health, PRA Health Sciences, and RTI International. His ability to forge strong teams and provide forward-looking insights positions him as a cornerstone of MMS’s future growth.
As Chief Financial Officer of MMS, Evan serves as the global head of the Accounting, Finance, Human Resources, and Talent Acquisition functions. Evan and his team are responsible for: financial planning and analysis, consolidations under US GAAP, treasury, HR leadership, and recruiting services. Evan’s role underscores MMS Holdings’ commitment to top-tier financial stewardship, talent development, and MMS’ growth-oriented mindset. His unique blend of experience and acumen promises to steer the company toward continued financial success.
What we have here at MMS is very special. We have great staff who deliver day in and day out for our clients and our organization. The expertise we bring to the market is top tier, and it shows through our customer satisfaction scores and our customer retention rates. In my organization, we aim to provide high quality services and solutioning for our internal and external partners. My team accomplishes this by exemplifying our corporate values, like “Wow the Customer” and “SOUL” (Sense Of Urgency Leadership). I’m very proud of the work we do at MMS and I’m excited to continue on our journey of evolution and growth as a company delivering value to our clients and bringing new therapies to patients swiftly and creatively.
Evan has a BS – Management degree from Virginia Tech (Pamplin College of Business) and an MBA from the College of William & Mary (Mason School of Business).
Suggested For You
perspectives
April 20th, 2026
The FDA Drug Shortage List Signals Deeper Concerns for the US Medicine Supply Chain
perspectives
April 15th, 2026
Decision-Making in Early-Phase Oncology Trials: Navigating Uncertainty with Evidence Frameworks
perspectives
April 8th, 2026
Four Pillars of My Success as a Clinical Trial Transparency Specialist
webinar
March 26th, 2026
Making the Right Decisions With Incomplete Evidence in Early-Phase Oncology Trials
perspectives
March 25th, 2026
REMS and Labeling Are Strategic Design Decisions, Not Late-Stage Add-Ons
perspectives
March 12th, 2026
AI in Pharma: Autopilot Is Not the Same as Removing the Pilot
webinar
April 30th, 2026
Inside FDA REMS Decision-Making: A Fireside Chat for Sponsors
perspectives
March 3rd, 2026
Modeling and Simulation in Clinical Trials: A Practical Approach to De-Risking Study Design
perspectives
February 25th, 2026
Integrating AI and Automation Into Clinical Trial Operations With Discipline and Transparency
perspectives
February 10th, 2026
A Conversation with MMS Founder and CEO Dr. Uma Sharma: Building MMS: 20 Years of People-First, Data-Led Drug Development
news
February 5th, 2026
MMS Appoints FDA Alum Dr. Somya Dunn as Senior Medical Director, Safety Risk Management to Expand Leadership in REMS and Pharmacovigilance Solutions
perspectives
February 3rd, 2026
A Conversation with MMS Founder and CEO Dr. Uma Sharma: Building MMS: 20 Years of People-First, Data-Led Drug Development